C3 downgrades revenue forecast after delays, low sales

Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, has announced that lower-than-expected sales and approval delays will keep it from reaching its $5-7 million revenue target for the 2007 financial year.